Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2020, Vol. 14 Issue (1) : 30-42    https://doi.org/10.1007/s11684-019-0721-9
REVIEW
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
Qian Wang, Linqi Zhang()
Comprehensive AIDS Research Center, Beijing Advanced Innovation Center for Structural Biology, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China
 Download: PDF(640 KB)   HTML
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract

Remarkable progress has been achieved for prophylactic and therapeutic interventions against human immunodeficiency virus type I (HIV-1) through antiretroviral therapy. However, vaccine development has remained challenging. Recent discoveries in broadly neutralizing monoclonal antibodies (bNAbs) has led to the development of multiple novel vaccine approaches for inducing bNAbs-like antibody response. Structural and dynamic studies revealed several vulnerable sites and states of the HIV-1 envelop glycoprotein (Env) during infection. Our review aims to highlight these discoveries and rejuvenate our endeavor in HIV-1 vaccine design and development.

Keywords HIV-1      broadly neutralizing antibodies      Env conformational states      vaccine design      SOSIP     
Corresponding Author(s): Linqi Zhang   
Just Accepted Date: 15 November 2019   Online First Date: 19 December 2019    Issue Date: 02 March 2020
 Cite this article:   
Qian Wang,Linqi Zhang. Broadly neutralizing antibodies and vaccine design against HIV-1 infection[J]. Front. Med., 2020, 14(1): 30-42.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-019-0721-9
https://academic.hep.com.cn/fmd/EN/Y2020/V14/I1/30
Ab Epitope IC50 geometric
mean (mg/mL)
Neutralization
breadth (%)
Number of viruses tested Clinical bNAb
development
VH mutation
(nt %)
CDRH3
length (aa)
Polyreactivity Preferentially
bind
References
(PMID)
PGDM1400 V1V2 0.003 83 106 Yes 24.3 34 No NA 25422458
PG9 V1V2 0.220 79 162 No 13 28 No State 1 Env 19729618, 30971821
PGT145 V1V2 0.290 78 162 No 18 31 No State 1 Env 21849977, 25298114
PG16 V1V2 0.150 73 162 No 12 28 No State 1 Env 19729618, 25298114
VRC26.25 V1V2 0.003 63 200 Yes 12 36 No NA 26468542
PGT128 V3 glycan 0.020 72 162 No 19 19 No State 1 Env 21849977, 25298114
PGT121 V3 glycan 0.030 70 162 Yes 17 24 No NA 21849977
10-1074 V3 glycan 0.022 66 178 Yes 26.7 24 NA State 1 Env 23115339, 30971821
BG18 V3 glycan 0.032 62 119 No 21.2 21 NA NA 28100831
N49-P7 CD4bs 0.100 100 117 No 24.1 21 NA NA 29731169
N6 CD4bs 0.038 98 181 Yes 31 15 No NA 27851912
VRC07-523 CD4bs 0.039 96 179 Yes 23.5 18 Yes NA 25142607
VRC01 CD4bs 0.369 90 208 Yes 32 14 Yes State 1 Env 20616233, 25298114
3BNC117 CD4bs 0.126 88 120 Yes 29.7 12 Yes State 1 Env 21764753, 30971821
NIH45-46 CD4bs 0.098 86 120 No 32.8 18 Yes NA 21764753
DH511.11P MPER 0.630 100 210 No 10.6 23 No NA 28783671
10E8 MPER 0.352 98 180 Yes 21 22 No NA 23151583
8ANC195 GP120/GP41 interface 1.189 68 120 No 28 22 Yes NA 21764753
35O22 GP120/GP41 interface 0.033 62 181 No 35 16 Yes NA 25186731
PGT151 Fusion peptide 0.008 66 117 No 20 28 No State 2 Env 24768347, 30971821
VRC34.01 Fusion peptide 0.320 49 208 No 15 13 NA NA 27174988
ACS202 Fusion peptide 0.142 45 75 No 16.1 22 Yes NA 27841852
SF12 Silent face center 0.200 62 119 No 17 23 No NA 31126879
VRC-PG05 Silent face center 0.800 27 208 No 9 17 NA NA 29548671
Tab.1  Overview of characteristics of representative second-generation bNAbs
Fig.1  Schematic diagram of HIV-1 and epitopes for bNAbs on trimeric HIV envelope spike glycoproteins.
Fig.2  Current status of bNAb development in preclinical and clinical studies.
1 RC Gallo, SZ Salahuddin, M Popovic, GM Shearer, M Kaplan, BF Haynes, TJ Palker, R Redfield, J Oleske, B Safai, et al.. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224(4648): 500–503
https://doi.org/10.1126/science.6200936 pmid: 6200936
2 F Barré-Sinoussi, JC Chermann, F Rey, MT Nugeyre, S Chamaret, J Gruest, C Dauguet, C Axler-Blin, F Vézinet-Brun, C Rouzioux, W Rozenbaum, L Montagnier. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220(4599): 868–871
https://doi.org/10.1126/science.6189183 pmid: 6189183
3 A Baghaei Lakeh, N Ghaffarzadegan. Global trends and regional variations in studies of HIV/AIDS. Sci Rep 2017; 7(1): 4170
https://doi.org/10.1038/s41598-017-04527-6 pmid: 28646150
4 UNAIDS. Country factsheets, China 2017.
5 X Hu, B Liang, C Zhou, J Jiang, J Huang, C Ning, J Liu, B Zhou, N Zang, J Lai, R Chen, Y Liao, P Pan, X Liu, G Lan, X Pang, L Ye, Z Shen, H Liang. HIV late presentation and advanced HIV disease among patients with newly diagnosed HIV/AIDS in Southwestern China: a large-scale cross-sectional study. AIDS Res Ther 2019; 16(1): 6
https://doi.org/10.1186/s12981-019-0221-7 pmid: 30876476
6 MJ Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, JM Gatell, P Domingo, R Paredes, M Sharkey, S Palmer, M Stevenson, B Clotet, J Blanco, J Martinez-Picado. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16(4): 460–465
https://doi.org/10.1038/nm.2111 pmid: 20228817
7 RC Gallo. A reflection on HIV/AIDS research after 25 years. Retrovirology 2006; 3(1): 72
https://doi.org/10.1186/1742-4690-3-72 pmid: 17054781
8 JD Siliciano, J Kajdas, D Finzi, TC Quinn, K Chadwick, JB Margolick, C Kovacs, SJ Gange, RF Siliciano. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9(6): 727–728
https://doi.org/10.1038/nm880 pmid: 12754504
9 D Finzi, J Blankson, JD Siliciano, JB Margolick, K Chadwick, T Pierson, K Smith, J Lisziewicz, F Lori, C Flexner, TC Quinn, RE Chaisson, E Rosenberg, B Walker, S Gange, J Gallant, RF Siliciano. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5(5): 512–517
https://doi.org/10.1038/8394 pmid: 10229227
10 Y Gao, PF McKay, JFS Mann. Advances in HIV-1 Vaccine Development. Viruses 2018; 10(4): E167
https://doi.org/10.3390/v10040167 pmid: 29614779
11 S Rerks-Ngarm, P Pitisuttithum, S Nitayaphan, J Kaewkungwal, J Chiu, R Paris, N Premsri, C Namwat, M de Souza, E Adams, M Benenson, S Gurunathan, J Tartaglia, JG McNeil, DP Francis, D Stablein, DL Birx, S Chunsuttiwat, C Khamboonruang, P Thongcharoen, ML Robb, NL Michael, P Kunasol, JH; MOPH-TAVEG Investigators. Kim Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209–2220
https://doi.org/10.1056/NEJMoa0908492 pmid: 19843557
12 JL Excler, ML Robb, JH Kim. HIV-1 vaccines: challenges and new perspectives. Hum Vaccin Immunother 2014; 10(6): 1734–1746
https://doi.org/10.4161/hv.28462 pmid: 24637946
13 PD Kwong, JR Mascola. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 2018; 48(5): 855–871
https://doi.org/10.1016/j.immuni.2018.04.029 pmid: 29768174
14 M Pancera, A Changela, PD Kwong. How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Curr Opin HIV AIDS 2017; 12(3): 229–240
https://doi.org/10.1097/COH.0000000000000360 pmid: 28422787
15 E Landais, PL Moore. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Retrovirology 2018; 15(1): 61
https://doi.org/10.1186/s12977-018-0443-0 pmid: 30185183
16 H Mouquet. Antibody B cell responses in HIV-1 infection. Trends Immunol 2014; 35(11): 549–561
https://doi.org/10.1016/j.it.2014.08.007 pmid: 25240985
17 DR Burton, J Pyati, R Koduri, SJ Sharp, GB Thornton, PW Parren, LS Sawyer, RM Hendry, N Dunlop, PL Nara, et al.. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266(5187): 1024–1027
https://doi.org/10.1126/science.7973652 pmid: 7973652
18 A Trkola, M Purtscher, T Muster, C Ballaun, A Buchacher, N Sullivan, K Srinivasan, J Sodroski, JP Moore, H Katinger. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70(2): 1100–1108
pmid: 8551569
19 T Muster, F Steindl, M Purtscher, A Trkola, A Klima, G Himmler, F Rüker, H Katinger. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67(11): 6642–6647
pmid: 7692082
20 MB Zwick, AF Labrijn, M Wang, C Spenlehauer, EO Saphire, JM Binley, JP Moore, G Stiegler, H Katinger, DR Burton, PW Parren. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75(22): 10892–10905
https://doi.org/10.1128/JVI.75.22.10892-10905.2001 pmid: 11602729
21 EO Saphire, PW Parren, R Pantophlet, MB Zwick, GM Morris, PM Rudd, RA Dwek, RL Stanfield, DR Burton, IA Wilson. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001; 293(5532): 1155–1159
https://doi.org/10.1126/science.1061692 pmid: 11498595
22 JR Mascola, MG Lewis, G Stiegler, D Harris, TC VanCott, D Hayes, MK Louder, CR Brown, CV Sapan, SS Frankel, Y Lu, ML Robb, H Katinger, DL Birx. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73(5): 4009–4018
pmid: 10196297
23 JR Mascola, G Stiegler, TC VanCott, H Katinger, CB Carpenter, CE Hanson, H Beary, D Hayes, SS Frankel, DL Birx, MG Lewis. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6(2): 207–210
https://doi.org/10.1038/72318 pmid: 10655111
24 TW Baba, V Liska, R Hofmann-Lehmann, J Vlasak, W Xu, S Ayehunie, LA Cavacini, MR Posner, H Katinger, G Stiegler, BJ Bernacky, TA Rizvi, R Schmidt, LR Hill, ME Keeling, Y Lu, JE Wright, TC Chou, RM Ruprecht. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6(2): 200–206
https://doi.org/10.1038/72309 pmid: 10655110
25 AJ Hessell, P Poignard, M Hunter, L Hangartner, DM Tehrani, WK Bleeker, PW Parren, PA Marx, DR Burton. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15(8): 951–954
https://doi.org/10.1038/nm.1974 pmid: 19525965
26 AJ Hessell, EG Rakasz, P Poignard, L Hangartner, G Landucci, DN Forthal, WC Koff, DI Watkins, DR Burton. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5(5): e1000433
https://doi.org/10.1371/journal.ppat.1000433 pmid: 19436712
27 AJ Hessell, EG Rakasz, DM Tehrani, M Huber, KL Weisgrau, G Landucci, DN Forthal, WC Koff, P Poignard, DI Watkins, DR Burton. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010; 84(3): 1302–1313
https://doi.org/10.1128/JVI.01272-09 pmid: 19906907
28 DA Calarese, CN Scanlan, MB Zwick, S Deechongkit, Y Mimura, R Kunert, P Zhu, MR Wormald, RL Stanfield, KH Roux, JW Kelly, PM Rudd, RA Dwek, H Katinger, DR Burton, IA Wilson. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003; 300(5628): 2065–2071
https://doi.org/10.1126/science.1083182 pmid: 12829775
29 G Yang, TM Holl, Y Liu, Y Li, X Lu, NI Nicely, TB Kepler, SM Alam, HX Liao, DW Cain, L Spicer, JL VandeBerg, BF Haynes, G Kelsoe. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 2013; 210(2): 241–256
https://doi.org/10.1084/jem.20121977 pmid: 23359068
30 BF Haynes, J Fleming, EW St Clair, H Katinger, G Stiegler, R Kunert, J Robinson, RM Scearce, K Plonk, HF Staats, TL Ortel, HX Liao, SM Alam. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308(5730): 1906–1908
https://doi.org/10.1126/science.1111781 pmid: 15860590
31 H Gruell, F Klein. Antibody-mediated prevention and treatment of HIV-1 infection. Retrovirology 2018; 15(1): 73
https://doi.org/10.1186/s12977-018-0455-9 pmid: 30445968
32 NA Doria-Rose, RM Klein, MM Manion, S O’Dell, A Phogat, B Chakrabarti, CW Hallahan, SA Migueles, J Wrammert, R Ahmed, M Nason, RT Wyatt, JR Mascola, M Connors. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009; 83(1): 188–199
https://doi.org/10.1128/JVI.01583-08 pmid: 18922865
33 I Mikell, DN Sather, SA Kalams, M Altfeld, G Alter, L Stamatatos. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011; 7(1): e1001251
https://doi.org/10.1371/journal.ppat.1001251 pmid: 21249232
34 ES Gray, MC Madiga, T Hermanus, PL Moore, CK Wibmer, NL Tumba, L Werner, K Mlisana, S Sibeko, C Williamson, SS Abdool Karim, L Morris; CAPRISA002 Study Team. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011; 85(10): 4828–4840
https://doi.org/10.1128/JVI.00198-11 pmid: 21389135
35 L Stamatatos, L Morris, DR Burton, JR Mascola. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15(8): 866–870
https://doi.org/10.1038/nm.1949 pmid: 19525964
36 DN Sather, J Armann, LK Ching, A Mavrantoni, G Sellhorn, Z Caldwell, X Yu, B Wood, S Self, S Kalams, L Stamatatos. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009; 83(2): 757–769
https://doi.org/10.1128/JVI.02036-08 pmid: 18987148
37 NA Doria-Rose, RM Klein, MG Daniels, S O’Dell, M Nason, A Lapedes, T Bhattacharya, SA Migueles, RT Wyatt, BT Korber, JR Mascola, M Connors. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010; 84(3): 1631–1636
https://doi.org/10.1128/JVI.01482-09 pmid: 19923174
38 AVAC. HIV-specific neutralizing antibodies—targets and research status 2019.
39 AVAC. Broadly neutralizing antibody combinations 2019.
40 JS McLellan, M Pancera, C Carrico, J Gorman, JP Julien, R Khayat, R Louder, R Pejchal, M Sastry, K Dai, S O’Dell, N Patel, S Shahzad-ul-Hussan, Y Yang, B Zhang, T Zhou, J Zhu, JC Boyington, GY Chuang, D Diwanji, I Georgiev, YD Kwon, D Lee, MK Louder, S Moquin, SD Schmidt, ZY Yang, M Bonsignori, JA Crump, SH Kapiga, NE Sam, BF Haynes, DR Burton, WC Koff, LM Walker, S Phogat, R Wyatt, J Orwenyo, LX Wang, J Arthos, CA Bewley, JR Mascola, GJ Nabel, WR Schief, AB Ward, IA Wilson, PD Kwong. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011; 480(7377): 336–343
https://doi.org/10.1038/nature10696 pmid: 22113616
41 JP Julien, JH Lee, A Cupo, CD Murin, R Derking, S Hoffenberg, MJ Caulfield, CR King, AJ Marozsan, PJ Klasse, RW Sanders, JP Moore, IA Wilson, AB Ward. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA 2013; 110(11): 4351–4356
https://doi.org/10.1073/pnas.1217537110 pmid: 23426631
42 LM Walker, SK Phogat, PY Chan-Hui, D Wagner, P Phung, JL Goss, T Wrin, MD Simek, S Fling, JL Mitcham, JK Lehrman, FH Priddy, OA Olsen, SM Frey, PW Hammond; Protocol G Principal Investigators, S Kaminsky, T Zamb, M Moyle, WC Koff, P Poignard, DR Burton, DR Burton. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326(5950): 285–289
https://doi.org/10.1126/science.1178746 pmid: 19729618
43 M Bonsignori, KK Hwang, X Chen, CY Tsao, L Morris, E Gray, DJ Marshall, JA Crump, SH Kapiga, NE Sam, F Sinangil, M Pancera, Y Yongping, B Zhang, J Zhu, PD Kwong, S O’Dell, JR Mascola, L Wu, GJ Nabel, S Phogat, MS Seaman, JF Whitesides, MA Moody, G Kelsoe, X Yang, J Sodroski, GM Shaw, DC Montefiori, TB Kepler, GD Tomaras, SM Alam, HX Liao, BF Haynes. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011; 85(19): 9998–10009
https://doi.org/10.1128/JVI.05045-11 pmid: 21795340
44 LM Walker, M Huber, KJ Doores, E Falkowska, R Pejchal, JP Julien, SK Wang, A Ramos, PY Chan-Hui, M Moyle, JL Mitcham, PW Hammond, OA Olsen, P Phung, S Fling, CH Wong, S Phogat, T Wrin, MD Simek; Protocol G Principal Investigators, WC Koff, IA Wilson, DR Burton, P Poignard, P Poignard. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477(7365): 466–470
https://doi.org/10.1038/nature10373 pmid: 21849977
45 D Sok, MJ van Gils, M Pauthner, JP Julien, KL Saye-Francisco, J Hsueh, B Briney, JH Lee, KM Le, PS Lee, Y Hua, MS Seaman, JP Moore, AB Ward, IA Wilson, RW Sanders, DR Burton. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci USA 2014; 111(49): 17624–17629
https://doi.org/10.1073/pnas.1415789111 pmid: 25422458
46 NA Doria-Rose, CA Schramm, J Gorman, PL Moore, JN Bhiman, BJ DeKosky, MJ Ernandes, IS Georgiev, HJ Kim, M Pancera, RP Staupe, HR Altae-Tran, RT Bailer, ET Crooks, A Cupo, A Druz, NJ Garrett, KH Hoi, R Kong, MK Louder, NS Longo, K McKee, M Nonyane, S O’Dell, RS Roark, RS Rudicell, SD Schmidt, DJ Sheward, C Soto, CK Wibmer, Y Yang, Z Zhang; NISC Comparative Sequencing Program, JC Mullikin, JM Binley, RW Sanders, IA Wilson, JP Moore, AB Ward, G Georgiou, C Williamson, SS Abdool Karim, L Morris, PD Kwong, L Shapiro, JR Mascola. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014; 509(7498): 55–62
https://doi.org/10.1038/nature13036 pmid: 24590074
47 H Mouquet, L Scharf, Z Euler, Y Liu, C Eden, JF Scheid, A Halper-Stromberg, PN Gnanapragasam, DI Spencer, MS Seaman, H Schuitemaker, T Feizi, MC Nussenzweig, PJ Bjorkman. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA 2012; 109(47): E3268–E3277
https://doi.org/10.1073/pnas.1217207109 pmid: 23115339
48 JP Julien, D Sok, R Khayat, JH Lee, KJ Doores, LM Walker, A Ramos, DC Diwanji, R Pejchal, A Cupo, U Katpally, RS Depetris, RL Stanfield, R McBride, AJ Marozsan, JC Paulson, RW Sanders, JP Moore, DR Burton, P Poignard, AB Ward, IA Wilson. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 2013; 9(5): e1003342
https://doi.org/10.1371/journal.ppat.1003342 pmid: 23658524
49 R Pejchal, KJ Doores, LM Walker, R Khayat, PS Huang, SK Wang, RL Stanfield, JP Julien, A Ramos, M Crispin, R Depetris, U Katpally, A Marozsan, A Cupo, S Maloveste, Y Liu, R McBride, Y Ito, RW Sanders, C Ogohara, JC Paulson, T Feizi, CN Scanlan, CH Wong, JP Moore, WC Olson, AB Ward, P Poignard, WR Schief, DR Burton, IA Wilson. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011; 334(6059): 1097–1103
https://doi.org/10.1126/science.1213256 pmid: 21998254
50 D Sok, M Pauthner, B Briney, JH Lee, KL Saye-Francisco, J Hsueh, A Ramos, KM Le, M Jones, JG Jardine, R Bastidas, A Sarkar, CH Liang, SS Shivatare, CY Wu, WR Schief, CH Wong, IA Wilson, AB Ward, J Zhu, P Poignard, DR Burton. A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans. Immunity 2016; 45(1): 31–45
https://doi.org/10.1016/j.immuni.2016.06.026 pmid: 27438765
51 AG Dalgleish, PC Beverley, PR Clapham, DH Crawford, MF Greaves, RA Weiss. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312(5996): 763–767
https://doi.org/10.1038/312763a0 pmid: 6096719
52 D Klatzmann, E Champagne, S Chamaret, J Gruest, D Guetard, T Hercend, JC Gluckman, L Montagnier. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312(5996): 767–768
https://doi.org/10.1038/312767a0 pmid: 6083454
53 T Zhou, L Xu, B Dey, AJ Hessell, D van Ryk, SH Xiang, X Yang, MY Zhang, MB Zwick, J Arthos, DR Burton, DS Dimitrov, J Sodroski, R Wyatt, GJ Nabel, PD Kwong. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445(7129): 732–737
https://doi.org/10.1038/nature05580 pmid: 17301785
54 T Zhou, RM Lynch, L Chen, P Acharya, X Wu, NA Doria-Rose, MG Joyce, D Lingwood, C Soto, RT Bailer, MJ Ernandes, R Kong, NS Longo, MK Louder, K McKee, S O’Dell, SD Schmidt, L Tran, Z Yang, A Druz, TS Luongo, S Moquin, S Srivatsan, Y Yang, B Zhang, A Zheng, M Pancera, T Kirys, IS Georgiev, T Gindin, HP Peng, AS Yang; NISC Comparative Sequencing Program, JC Mullikin, MD Gray, L Stamatatos, DR Burton, WC Koff, MS Cohen, BF Haynes, JP Casazza, M Connors, D Corti, A Lanzavecchia, QJ Sattentau, RA Weiss, AP West Jr, PJ Bjorkman, JF Scheid, MC Nussenzweig, L Shapiro, JR Mascola, PD Kwong, PD Kwong. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 2015; 161(6): 1280–1292
https://doi.org/10.1016/j.cell.2015.05.007 pmid: 26004070
55 MM Sajadi, A Dashti, Z Rikhtegaran Tehrani, WD Tolbert, MS Seaman, X Ouyang, N Gohain, M Pazgier, D Kim, G Cavet, J Yared, RR Redfield, GK Lewis, AL DeVico. Identification of near-Pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses. Cell 2018; 173(7): 1783–1795.e14
56 X Wu, ZY Yang, Y Li, CM Hogerkorp, WR Schief, MS Seaman, T Zhou, SD Schmidt, L Wu, L Xu, NS Longo, K McKee, S O’Dell, MK Louder, DL Wycuff, Y Feng, M Nason, N Doria-Rose, M Connors, PD Kwong, M Roederer, RT Wyatt, GJ Nabel, JR Mascola. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329(5993): 856–861
https://doi.org/10.1126/science.1187659 pmid: 20616233
57 J Huang, BH Kang, E Ishida, T Zhou, T Griesman, Z Sheng, F Wu, NA Doria-Rose, B Zhang, K McKee, S O’Dell, GY Chuang, A Druz, IS Georgiev, CA Schramm, A Zheng, MG Joyce, M Asokan, A Ransier, S Darko, SA Migueles, RT Bailer, MK Louder, SM Alam, R Parks, G Kelsoe, T Von Holle, BF Haynes, DC Douek, V Hirsch, MS Seaman, L Shapiro, JR Mascola, PD Kwong, M Connors. Identification of a CD4-binding-site antibody to HIV that evolved near-Pan neutralization breadth. Immunity 2016; 45(5): 1108–1121
https://doi.org/10.1016/j.immuni.2016.10.027 pmid: 27851912
58 RS Rudicell, YD Kwon, SY Ko, A Pegu, MK Louder, IS Georgiev, X Wu, J Zhu, JC Boyington, X Chen, W Shi, ZY Yang, NA Doria-Rose, K McKee, S O’Dell, SD Schmidt, GY Chuang, A Druz, C Soto, Y Yang, B Zhang, T Zhou, JP Todd, KE Lloyd, J Eudailey, KE Roberts, BR Donald, RT Bailer, J Ledgerwood; NISC Comparative Sequencing Program, JC Mullikin, L Shapiro, RA Koup, BS Graham, MC Nason, M Connors, BF Haynes, SS Rao, M Roederer, PD Kwong, JR Mascola, GJ Nabel, GJ Nabel. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 2014; 88(21): 12669–12682
https://doi.org/10.1128/JVI.02213-14 pmid: 25142607
59 JF Scheid, H Mouquet, B Ueberheide, R Diskin, F Klein, TY Oliveira, J Pietzsch, D Fenyo, A Abadir, K Velinzon, A Hurley, S Myung, F Boulad, P Poignard, DR Burton, F Pereyra, DD Ho, BD Walker, MS Seaman, PJ Bjorkman, BT Chait, MC Nussenzweig. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333(6049): 1633–1637
https://doi.org/10.1126/science.1207227 pmid: 21764753
60 P Zhou, H Wang, M Fang, Y Li, H Wang, S Shi, Z Li, J Wu, X Han, X Shi, H Shang, T Zhou, L Zhang. Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies. PLoS Pathog 2019; 15(6): e1007819
https://doi.org/10.1371/journal.ppat.1007819 pmid: 31194843
61 J Huang, G Ofek, L Laub, MK Louder, NA Doria-Rose, NS Longo, H Imamichi, RT Bailer, B Chakrabarti, SK Sharma, SM Alam, T Wang, Y Yang, B Zhang, SA Migueles, R Wyatt, BF Haynes, PD Kwong, JR Mascola, M Connors. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012; 491(7424): 406–412
https://doi.org/10.1038/nature11544 pmid: 23151583
62 SJ Krebs, YD Kwon, CA Schramm, WH Law, G Donofrio, KH Zhou, S Gift, V Dussupt, IS Georgiev, S Schatzle, JR McDaniel, YT Lai, M Sastry, B Zhang, MC Jarosinski, A Ransier, AL Chenine, M Asokan, RT Bailer, M Bose, A Cagigi, EM Cale, GY Chuang, S Darko, JI Driscoll, A Druz, J Gorman, F Laboune, MK Louder, K McKee, L Mendez, MA Moody, AM O'Sullivan, C Owen, D Peng, R Rawi, E Sanders-Buell, CH Shen, AR Shiakolas, T Stephens, Y Tsybovsky, C Tucker, R Verardi, K Wang, J Zhou, T Zhou, G Georgiou, SM Alam, BF Haynes, M Rolland, GR Matyas, VR Polonis, AB McDermott, DC Douek, L Shapiro, S Tovanabutra, NL Michael, JR Mascola, ML Robb, PD Kwong, NA Doria-Rose. Longitudinal analysis reveals early development of three MPER-directed neutralizing antibody lineages from an HIV-1-infected individual. Immunity 2019; 50(3): 677–691.e13
63 J Huang, BH Kang, M Pancera, JH Lee, T Tong, Y Feng, H Imamichi, IS Georgiev, GY Chuang, A Druz, NA Doria-Rose, L Laub, K Sliepen, MJ van Gils, AT de la Peña, R Derking, PJ Klasse, SA Migueles, RT Bailer, M Alam, P Pugach, BF Haynes, RT Wyatt, RW Sanders, JM Binley, AB Ward, JR Mascola, PD Kwong, M Connors. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014; 515(7525): 138–142
https://doi.org/10.1038/nature13601 pmid: 25186731
64 L Scharf, JF Scheid, JH Lee, AP West Jr, C Chen, H Gao, PN Gnanapragasam, R Mares, MS Seaman, AB Ward, MC Nussenzweig, PJ Bjorkman. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Reports 2014; 7(3): 785–795
https://doi.org/10.1016/j.celrep.2014.04.001 pmid: 24767986
65 L Scharf, H Wang, H Gao, S Chen, AW McDowall, PJ Bjorkman. Broadly neutralizing antibody 8ANC195 recognizes closed and open states of HIV-1 Env. Cell 2015; 162(6): 1379–1390
https://doi.org/10.1016/j.cell.2015.08.035 pmid: 26359989
66 R Kong, K Xu, T Zhou, P Acharya, T Lemmin, K Liu, G Ozorowski, C Soto, JD Taft, RT Bailer, EM Cale, L Chen, CW Choi, GY Chuang, NA Doria-Rose, A Druz, IS Georgiev, J Gorman, J Huang, MG Joyce, MK Louder, X Ma, K McKee, S O’Dell, M Pancera, Y Yang, SC Blanchard, W Mothes, DR Burton, WC Koff, M Connors, AB Ward, PD Kwong, JR Mascola. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 2016; 352(6287): 828–833
https://doi.org/10.1126/science.aae0474 pmid: 27174988
67 E Falkowska, KM Le, A Ramos, KJ Doores, JH Lee, C Blattner, A Ramirez, R Derking, MJ van Gils, CH Liang, R Mcbride, B von Bredow, SS Shivatare, CY Wu, PY Chan-Hui, Y Liu, T Feizi, MB Zwick, WC Koff, MS Seaman, K Swiderek, JP Moore, D Evans, JC Paulson, CH Wong, AB Ward, IA Wilson, RW Sanders, P Poignard, DR Burton. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014; 40(5): 657–668
https://doi.org/10.1016/j.immuni.2014.04.009 pmid: 24768347
68 MJ van Gils, TLGM van den Kerkhof, G Ozorowski, CA Cottrell, D Sok, M Pauthner, J Pallesen, N de Val, A Yasmeen, SW de Taeye, A Schorcht, S Gumbs, I Johanna, K Saye-Francisco, CH Liang, E Landais, X Nie, LK Pritchard, M Crispin, G Kelsoe, IA Wilson, H Schuitemaker, PJ Klasse, JP Moore, DR Burton, AB Ward, RW Sanders. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat Microbiol 2016; 2(2): 16199
https://doi.org/10.1038/nmicrobiol.2016.199 pmid: 27841852
69 M Yuan, CA Cottrell, G Ozorowski, MJ van Gils, S Kumar, NC Wu, A Sarkar, JL Torres, N de Val, J Copps, JP Moore, RW Sanders, AB Ward, IA Wilson. Conformational plasticity in the HIV-1 fusion peptide facilitates recognition by broadly neutralizing antibodies. Cell Host Microbe 2019; 25(6): 873–883.e5
70 K Xu, P Acharya, R Kong, C Cheng, GY Chuang, K Liu, MK Louder, S O’Dell, R Rawi, M Sastry, CH Shen, B Zhang, T Zhou, M Asokan, RT Bailer, M Chambers, X Chen, CW Choi, VP Dandey, NA Doria-Rose, A Druz, ET Eng, SK Farney, KE Foulds, H Geng, IS Georgiev, J Gorman, KR Hill, AJ Jafari, YD Kwon, YT Lai, T Lemmin, K McKee, TY Ohr, L Ou, D Peng, AP Rowshan, Z Sheng, JP Todd, Y Tsybovsky, EG Viox, Y Wang, H Wei, Y Yang, AF Zhou, R Chen, L Yang, DG Scorpio, AB McDermott, L Shapiro, B Carragher, CS Potter, JR Mascola, PD Kwong. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat Med 2018; 24(6): 857–867
https://doi.org/10.1038/s41591-018-0042-6 pmid: 29867235
71 R Kong, H Duan, Z Sheng, K Xu, P Acharya, X Chen, C Cheng, AS Dingens, J Gorman, M Sastry, CH Shen, B Zhang, T Zhou, GY Chuang, CW Chao, Y Gu, AJ Jafari, MK Louder, S O’Dell, AP Rowshan, EG Viox, Y Wang, CW Choi, MM Corcoran, AR Corrigan, VP Dandey, ET Eng, H Geng, KE Foulds, Y Guo, YD Kwon, B Lin, K Liu, RD Mason, MC Nason, TY Ohr, L Ou, R Rawi, EK Sarfo, A Schon, JP Todd, S Wang, H Wei, W Wu, NCS Program, JC Mullikin, RT Bailer, NA Doria-Rose, GB Karlsson Hedestam, DG Scorpio, J Overbaugh, JD Bloom, B Carragher, CS Potter, L Shapiro, PD Kwong, JR Mascola. Antibody lineages with vaccine-induced antigen-binding hotspots develop broad HIV neutralization. Cell 2019; 178(3): 567–584.e19
72 T Zhou, A Zheng, U Baxa, GY Chuang, IS Georgiev, R Kong, S O’Dell, S Shahzad-Ul-Hussan, CH Shen, Y Tsybovsky, RT Bailer, SK Gift, MK Louder, K McKee, R Rawi, CH Stevenson, GBE Stewart-Jones, JD Taft, E Waltari, Y Yang, B Zhang, SS Shivatare, VS Shivatare, CD Lee, CY Wu, NCS Program, JC Mullikin, CA Bewley, DR Burton, VR Polonis, L Shapiro, CH Wong, JR Mascola, PD Kwong, X Wu. A neutralizing antibody recognizing primarily N-linked glycan targets the silent face of the HIV envelope. Immunity 2018; 48(3): 500–513.e6
73 T Schoofs, CO Barnes, N Suh-Toma, J Golijanin, P Schommers, H Gruell, AP West, Jr., F Bach, YE Lee, L Nogueira, IS Georgiev, RT Bailer, J Czartoski, JR Mascola, MS Seaman, MJ McElrath, NA Doria-Rose, F Klein, MC Nussenzweig, PJ Bjorkman. Broad and potent neutralizing antibodies recognize the silent face of the HIV envelope. Immunity 2019; 50(6): 1513–1529.e9
74 JR Mascola, BF Haynes. HIV-1 neutralizing antibodies: understanding nature’s pathways. Immunol Rev 2013; 254(1): 225–244
https://doi.org/10.1111/imr.12075 pmid: 23772623
75 F Klein, H Mouquet, P Dosenovic, JF Scheid, L Scharf, MC Nussenzweig. Antibodies in HIV-1 vaccine development and therapy. Science 2013; 341(6151): 1199–1204
https://doi.org/10.1126/science.1241144 pmid: 24031012
76 X Wu, T Zhou, J Zhu, B Zhang, I Georgiev, C Wang, X Chen, NS Longo, M Louder, K McKee, S O’Dell, S Perfetto, SD Schmidt, W Shi, L Wu, Y Yang, ZY Yang, Z Yang, Z Zhang, M Bonsignori, JA Crump, SH Kapiga, NE Sam, BF Haynes, M Simek, DR Burton, WC Koff, NA Doria-Rose, M Connors; Program NISC Comparative Sequencing, JC Mullikin, GJ Nabel, M Roederer, L Shapiro, PD Kwong, JR Mascola, JR Mascola. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011; 333(6049): 1593–1602
https://doi.org/10.1126/science.1207532 pmid: 21835983
77 HX Liao, R Lynch, T Zhou, F Gao, SM Alam, SD Boyd, AZ Fire, KM Roskin, CA Schramm, Z Zhang, J Zhu, L Shapiro; Program NISC Comparative Sequencing, JC Mullikin, S Gnanakaran, P Hraber, K Wiehe, G Kelsoe, G Yang, SM Xia, DC Montefiori, R Parks, KE Lloyd, RM Scearce, KA Soderberg, M Cohen, G Kamanga, MK Louder, LM Tran, Y Chen, F Cai, S Chen, S Moquin, X Du, MG Joyce, S Srivatsan, B Zhang, A Zheng, GM Shaw, BH Hahn, TB Kepler, BT Korber, PD Kwong, JR Mascola, BF Haynes, BF Haynes. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496(7446): 469–476
https://doi.org/10.1038/nature12053 pmid: 23552890
78 M Lu, X Ma, LR Castillo-Menendez, J Gorman, N Alsahafi, U Ermel, DS Terry, M Chambers, D Peng, B Zhang, T Zhou, N Reichard, K Wang, JR Grover, BP Carman, MR Gardner, I Nikić-Spiegel, A Sugawara, J Arthos, EA Lemke, AB Smith 3rd, M Farzan, C Abrams, JB Munro, AB McDermott, A Finzi, PD Kwong, SC Blanchard, JG Sodroski, W Mothes. Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. Nature 2019; 568(7752): 415–419
https://doi.org/10.1038/s41586-019-1101-y pmid: 30971821
79 MS Cohen, GM Shaw, AJ McMichael, BF Haynes. Acute HIV-1 infection. N Engl J Med 2011; 364(20): 1943–1954
https://doi.org/10.1056/NEJMra1011874 pmid: 21591946
80 AJ McMichael, P Borrow, GD Tomaras, N Goonetilleke, BF Haynes. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10(1): 11–23
https://doi.org/10.1038/nri2674 pmid: 20010788
81 F Breden, C Lepik, NS Longo, M Montero, PE Lipsky, JK Scott. Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 2011; 6(3): e16857
https://doi.org/10.1371/journal.pone.0016857 pmid: 21479208
82 JF Scheid, H Mouquet, N Feldhahn, MS Seaman, K Velinzon, J Pietzsch, RG Ott, RM Anthony, H Zebroski, A Hurley, A Phogat, B Chakrabarti, Y Li, M Connors, F Pereyra, BD Walker, H Wardemann, D Ho, RT Wyatt, JR Mascola, JV Ravetch, MC Nussenzweig. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458(7238): 636–640
https://doi.org/10.1038/nature07930 pmid: 19287373
83 T Tiller, M Tsuiji, S Yurasov, K Velinzon, MC Nussenzweig, H Wardemann. Autoreactivity in human IgG+ memory B cells. Immunity 2007; 26(2): 205–213
https://doi.org/10.1016/j.immuni.2007.01.009 pmid: 17306569
84 F Klein, R Diskin, JF Scheid, C Gaebler, H Mouquet, IS Georgiev, M Pancera, T Zhou, RB Incesu, BZ Fu, PN Gnanapragasam, TY Oliveira, MS Seaman, PD Kwong, PJ Bjorkman, MC Nussenzweig. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013; 153(1): 126–138
https://doi.org/10.1016/j.cell.2013.03.018 pmid: 23540694
85 TB Kepler, HX Liao, SM Alam, R Bhaskarabhatla, R Zhang, C Yandava, S Stewart, K Anasti, G Kelsoe, R Parks, KE Lloyd, C Stolarchuk, J Pritchett, E Solomon, E Friberg, L Morris, SS Karim, MS Cohen, E Walter, MA Moody, X Wu, HR Altae-Tran, IS Georgiev, PD Kwong, SD Boyd, AZ Fire, JR Mascola, BF Haynes. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe 2014; 16(3): 304–313
https://doi.org/10.1016/j.chom.2014.08.006 pmid: 25211073
86 X Xiao, W Chen, Y Feng, Z Zhu, P Prabakaran, Y Wang, MY Zhang, NS Longo, DS Dimitrov. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 2009; 390(3): 404–409
https://doi.org/10.1016/j.bbrc.2009.09.029 pmid: 19748484
87 HX Liao, X Chen, S Munshaw, R Zhang, DJ Marshall, N Vandergrift, JF Whitesides, X Lu, JS Yu, KK Hwang, F Gao, M Markowitz, SL Heath, KJ Bar, PA Goepfert, DC Montefiori, GC Shaw, SM Alam, DM Margolis, TN Denny, SD Boyd, E Marshal, M Egholm, BB Simen, B Hanczaruk, AZ Fire, G Voss, G Kelsoe, GD Tomaras, MA Moody, TB Kepler, BF Haynes. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 2011; 208(11): 2237–2249
https://doi.org/10.1084/jem.20110363 pmid: 21987658
88 A Flemming. HIV: sequential vaccine elicits broadly neutralizing antibodies. Nat Rev Drug Discov 2016; 15(11): 748–749
https://doi.org/10.1038/nrd.2016.228 pmid: 27807354
89 H Wardemann, S Yurasov, A Schaefer, JW Young, E Meffre, MC Nussenzweig. Predominant autoantibody production by early human B cell precursors. Science 2003; 301(5638): 1374–1377
https://doi.org/10.1126/science.1086907 pmid: 12920303
90 H Mouquet, JF Scheid, MJ Zoller, M Krogsgaard, RG Ott, S Shukair, MN Artyomov, J Pietzsch, M Connors, F Pereyra, BD Walker, DD Ho, PC Wilson, MS Seaman, HN Eisen, AK Chakraborty, TJ Hope, JV Ravetch, H Wardemann, MC Nussenzweig. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010; 467(7315): 591–595
https://doi.org/10.1038/nature09385 pmid: 20882016
91 P Zhu, J Liu, J Bess Jr, E Chertova, JD Lifson, H Grisé, GA Ofek, KA Taylor, KH Roux. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006; 441(7095): 847–852
https://doi.org/10.1038/nature04817 pmid: 16728975
92 A Herschhorn, J Sodroski. An entry-competent intermediate state of the HIV-1 envelope glycoproteins. Receptors Clin Investig 2017; 4(1): e1544
pmid: 28752105
93 T Bruel, O Schwartz. HIV-1 envelope FRETted over by antibodies. Cell Host Microbe 2019; 25(6): 767–768
https://doi.org/10.1016/j.chom.2019.05.009 pmid: 31194935
94 X Ma, M Lu, J Gorman, DS Terry, X Hong, Z Zhou, H Zhao, RB Altman, J Arthos, SC Blanchard, PD Kwong, JB Munro, W Mothes. HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations. eLife 2018; 7:e34271
https://doi.org/10.7554/eLife.34271 pmid: 29561264
95 A Herschhorn, X Ma, C Gu, JD Ventura, L Castillo-Menendez, B Melillo, DS Terry, AB Smith 3rd, SC Blanchard, JB Munro, W Mothes, A Finzi, J Sodroski. Release of gp120 restraints leads to an entry-competent intermediate state of the HIV-1 envelope glycoproteins. MBio 2016; 7(5): e01598-16
https://doi.org/10.1128/mBio.01598-16 pmid: 27795397
96 A Herschhorn, C Gu, F Moraca, X Ma, M Farrell, AB Smith 3rd, M Pancera, PD Kwong, A Schön, E Freire, C Abrams, SC Blanchard, W Mothes, JG Sodroski. The b20-b21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions. Nat Commun 2017; 8(1): 1049
https://doi.org/10.1038/s41467-017-01119-w pmid: 29051495
97 Q Wang, L Liu, W Ren, A Gettie, H Wang, Q Liang, X Shi, DC Montefiori, T Zhou, L Zhang. A single substitution in gp41 modulates the neutralization profile of SHIV during invivo adaptation. Cell Reports 2019; 27(9): 2593–2607.e5
https://doi.org/10.1016/j.celrep.2019.04.108 pmid: 31141685
98 JB Munro, J Gorman, X Ma, Z Zhou, J Arthos, DR Burton, WC Koff, JR Courter, AB Smith 3rd, PD Kwong, SC Blanchard, W Mothes. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 2014; 346(6210): 759–763
https://doi.org/10.1126/science.1254426 pmid: 25298114
99 N Alsahafi, N Bakouche, M Kazemi, J Richard, S Ding, S Bhattacharyya, D Das, SP Anand, J Prevost, WD Tolbert, H Lu, H Medjahed, G Gendron-Lepage, GG Ortega Delgado, S Kirk, B Melillo, W Mothes, J Sodroski, AB Smith, 3rd, DE Kaufmann, X Wu, M Pazgier, I Rouiller, A Finzi, JB Munro. An asymmetric opening of HIV-1 envelope mediates antibody-dependent cellular cytotoxicity. Cell Host Microbe 2019; 25(4): 578–587.e5
100 RW Sanders, R Derking, A Cupo, JP Julien, A Yasmeen, N de Val, HJ Kim, C Blattner, AT de la Peña, J Korzun, M Golabek, K de Los Reyes, TJ Ketas, MJ van Gils, CR King, IA Wilson, AB Ward, PJ Klasse, JP Moore. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013; 9(9): e1003618
https://doi.org/10.1371/journal.ppat.1003618 pmid: 24068931
101 YD Kwon, M Pancera, P Acharya, IS Georgiev, ET Crooks, J Gorman, MG Joyce, M Guttman, X Ma, S Narpala, C Soto, DS Terry, Y Yang, T Zhou, G Ahlsen, RT Bailer, M Chambers, GY Chuang, NA Doria-Rose, A Druz, MA Hallen, A Harned, T Kirys, MK Louder, S O’Dell, G Ofek, K Osawa, M Prabhakaran, M Sastry, GB Stewart-Jones, J Stuckey, PV Thomas, T Tittley, C Williams, B Zhang, H Zhao, Z Zhou, BR Donald, LK Lee, S Zolla-Pazner, U Baxa, A Schön, E Freire, L Shapiro, KK Lee, J Arthos, JB Munro, SC Blanchard, W Mothes, JM Binley, AB McDermott, JR Mascola, PD Kwong. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol 2015; 22(7): 522–531
https://doi.org/10.1038/nsmb.3051 pmid: 26098315
102 JH Lee, G Ozorowski, AB Ward. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 2016; 351(6277): 1043–1048
https://doi.org/10.1126/science.aad2450 pmid: 26941313
103 SK Sharma, N de Val, S Bale, J Guenaga, K Tran, Y Feng, V Dubrovskaya, AB Ward, RT Wyatt. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Reports 2015; 11(4): 539–550
https://doi.org/10.1016/j.celrep.2015.03.047 pmid: 25892233
104 J Guenaga, F Garces, N de Val, RL Stanfield, V Dubrovskaya, B Higgins, B Carrette, AB Ward, IA Wilson, RT Wyatt. Glycine substitution at helix-to-coil transitions facilitates the structural determination of a stabilized subtype C HIV envelope glycoprotein. Immunity 2017; 46(5): 792–803.e3
105 L Kong, L He, N de Val, N Vora, CD Morris, P Azadnia, D Sok, B Zhou, DR Burton, AB Ward, IA Wilson, J Zhu. Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat Commun 2016; 7(1): 12040
https://doi.org/10.1038/ncomms12040 pmid: 27349805
106 JP Julien, A Cupo, D Sok, RL Stanfield, D Lyumkis, MC Deller, PJ Klasse, DR Burton, RW Sanders, JP Moore, AB Ward, IA Wilson. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013; 342(6165): 1477–1483
https://doi.org/10.1126/science.1245625 pmid: 24179159
107 D Lyumkis, JP Julien, N de Val, A Cupo, CS Potter, PJ Klasse, DR Burton, RW Sanders, JP Moore, B Carragher, IA Wilson, AB Ward. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013; 342(6165): 1484–1490
https://doi.org/10.1126/science.1245627 pmid: 24179160
108 L He, S Kumar, JD Allen, D Huang, X Lin, CJ Mann, KL Saye-Francisco, J Copps, A Sarkar, GS Blizard, G Ozorowski, D Sok, M Crispin, AB Ward, D Nemazee, DR Burton, IA Wilson, J Zhu. HIV-1 vaccine design through minimizing envelope metastability. Sci Adv 2018; 4(11): eaau6769
109 A Sarkar, S Bale, AJ Behrens, S Kumar, SK Sharma, N de Val, J Pallesen, A Irimia, DC Diwanji, RL Stanfield, AB Ward, M Crispin, RT Wyatt, IA Wilson. Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. Nat Commun 2018; 9(1): 1956
https://doi.org/10.1038/s41467-018-04272-y pmid: 29769533
110 H Wang, X Chen, D Wang, C Yao, Q Wang, J Xie, X Shi, Y Xiang, W Liu, L Zhang. Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses. J Biol Chem 2018; 293(3): 830–846
https://doi.org/10.1074/jbc.M117.816447 pmid: 29187598
111 T Zhou, I Georgiev, X Wu, ZY Yang, K Dai, A Finzi, YD Kwon, JF Scheid, W Shi, L Xu, Y Yang, J Zhu, MC Nussenzweig, J Sodroski, L Shapiro, GJ Nabel, JR Mascola, PD Kwong. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329(5993): 811–817
https://doi.org/10.1126/science.1192819 pmid: 20616231
112 NT Freund, JA Horwitz, L Nogueira, SA Sievers, L Scharf, JF Scheid, A Gazumyan, C Liu, K Velinzon, A Goldenthal, RW Sanders, JP Moore, PJ Bjorkman, MS Seaman, BD Walker, F Klein, MC Nussenzweig. A new glycan-dependent CD4-binding site neutralizing antibody exerts pressure on HIV-1 in vivo. PLoS Pathog 2015; 11(10): e1005238
https://doi.org/10.1371/journal.ppat.1005238 pmid: 26516768
113 AJ Borst, CE Weidle, MD Gray, B Frenz, J Snijder, MG Joyce, IS Georgiev, GB Stewart-Jones, PD Kwong, AT McGuire, F DiMaio, L Stamatatos, M Pancera, D Veesler. Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. eLife 2018; 7: e37688
https://doi.org/10.7554/eLife.37688 pmid: 30403372
114 J Jardine, JP Julien, S Menis, T Ota, O Kalyuzhniy, A McGuire, D Sok, PS Huang, S MacPherson, M Jones, T Nieusma, J Mathison, D Baker, AB Ward, DR Burton, L Stamatatos, D Nemazee, IA Wilson, WR Schief. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340(6133): 711–716
https://doi.org/10.1126/science.1234150 pmid: 23539181
115 JG Jardine, DW Kulp, C Havenar-Daughton, A Sarkar, B Briney, D Sok, F Sesterhenn, J Ereño-Orbea, O Kalyuzhniy, I Deresa, X Hu, S Spencer, M Jones, E Georgeson, Y Adachi, M Kubitz, AC deCamp, JP Julien, IA Wilson, DR Burton, S Crotty, WR Schief. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 2016; 351(6280): 1458–1463
https://doi.org/10.1126/science.aad9195 pmid: 27013733
116 M Pauthner, C Havenar-Daughton, D Sok, JP Nkolola, R Bastidas, AV Boopathy, DG Carnathan, A Chandrashekar, KM Cirelli, CA Cottrell, AM Eroshkin, J Guenaga, K Kaushik, DW Kulp, J Liu, LE McCoy, AL Oom, G Ozorowski, KW Post, SK Sharma, JM Steichen, SW de Taeye, T Tokatlian, A Torrents de la Pena, ST Butera, CC LaBranche, DC Montefiori, G Silvestri, IA Wilson, DJ Irvine, RW Sanders, WR Schief, AB Ward, RT Wyatt, DH Barouch, S Crotty, DR Burton. Elicitation of robust Tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches. Immunity 2017; 46(6): 1073–1088.e6
117 A Torrents de la Peña, SW de Taeye, K Sliepen, CC LaBranche, JA Burger, EE Schermer, DC Montefiori, JP Moore, PJ Klasse, RW Sanders. Immunogenicity in rabbits of HIV-1 SOSIP trimers from clades A, B, and C, given individually, sequentially, or in combination. J Virol 2018; 92(8): e01957-17
https://doi.org/10.1128/JVI.01957-17 pmid: 29367243
118 RW Sanders, MJ van Gils, R Derking, D Sok, TJ Ketas, JA Burger, G Ozorowski, A Cupo, C Simonich, L Goo, H Arendt, HJ Kim, JH Lee, P Pugach, M Williams, G Debnath, B Moldt, MJ van Breemen, G Isik, M Medina-Ramírez, JW Back, WC Koff, JP Julien, EG Rakasz, MS Seaman, M Guttman, KK Lee, PJ Klasse, C LaBranche, WR Schief, IA Wilson, J Overbaugh, DR Burton, AB Ward, DC Montefiori, H Dean, JP Moore. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015; 349(6244): aac4223
https://doi.org/10.1126/science.aac4223 pmid: 26089353
119 PJ Klasse, CC LaBranche, TJ Ketas, G Ozorowski, A Cupo, P Pugach, RP Ringe, M Golabek, MJ van Gils, M Guttman, KK Lee, IA Wilson, ST Butera, AB Ward, DC Montefiori, RW Sanders, JP Moore. Sequential and simultaneous immunization of rabbits with HIV-1 envelope glycoprotein SOSIP.664 trimers from clades A, B and C. PLoS Pathog 2016; 12(9): e1005864
https://doi.org/10.1371/journal.ppat.1005864 pmid: 27627672
120 SW de Taeye, G Ozorowski, A Torrents de la Peña, M Guttman, JP Julien, TL van den Kerkhof, JA Burger, LK Pritchard, P Pugach, A Yasmeen, J Crampton, J Hu, I Bontjer, JL Torres, H Arendt, J DeStefano, WC Koff, H Schuitemaker, D Eggink, B Berkhout, H Dean, C LaBranche, S Crotty, M Crispin, DC Montefiori, PJ Klasse, KK Lee, JP Moore, IA Wilson, AB Ward, RW Sanders. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 2015; 163(7): 1702–1715
https://doi.org/10.1016/j.cell.2015.11.056 pmid: 26687358
121 JK Hu, JC Crampton, A Cupo, T Ketas, MJ van Gils, K Sliepen, SW de Taeye, D Sok, G Ozorowski, I Deresa, R Stanfield, AB Ward, DR Burton, PJ Klasse, RW Sanders, JP Moore, S Crotty. Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity. J Virol 2015; 89(20): 10383–10398
https://doi.org/10.1128/JVI.01653-15 pmid: 26246566
122 Y Feng, K Tran, S Bale, S Kumar, J Guenaga, R Wilson, N de Val, H Arendt, J DeStefano, AB Ward, RT Wyatt. Thermostability of well-ordered HIV spikes correlates with the elicitation of autologous Tier 2 neutralizing antibodies. PLoS Pathog 2016; 12(8): e1005767
https://doi.org/10.1371/journal.ppat.1005767 pmid: 27487086
123 K Koch, S Kalusche, JL Torres, RL Stanfield, W Danquah, K Khazanehdari, H von Briesen, ER Geertsma, IA Wilson, U Wernery, F Koch-Nolte, AB Ward, U Dietrich. Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers. Sci Rep 2017; 7(1): 8390
https://doi.org/10.1038/s41598-017-08273-7 pmid: 28827559
124 D Sok, KM Le, M Vadnais, KL Saye-Francisco, JG Jardine, JL Torres, ZT Berndsen, L Kong, R Stanfield, J Ruiz, A Ramos, CH Liang, PL Chen, MF Criscitiello, W Mwangi, IA Wilson, AB Ward, VV Smider, DR Burton. Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature 2017; 548(7665): 108–111
https://doi.org/10.1038/nature23301 pmid: 28726771
[1] Jingjing Yan, Shuye Zhang, Jun Sun, Jianqing Xu, Xiaoyang Zhang. Irreversible phenotypic perturbation and functional impairment of B cells during HIV-1 infection[J]. Front. Med., 2017, 11(4): 536-547.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed